CD8A and acute myeloid leukemia: In a model of acute myeloid leukemia (AML), in which leukemia antigen-specific CD8+ T cells become inactivated and host type I IFN secretion becomes impaired, direct STING activation by intravenous administration of DMXAA or CMA can ectopically induce type I IFN release to activate host DCs and T cells and maintain immunological memory, thereby improving the survival of the leukemic mice [165, 169].